November 20, 2012
CINCINNATI, OH — Medpace, a privately held, global, full-service contract research organization (CRO) announced that it has acquired MediTech Strategic Consultants B.V. (MediTech), a European CRO dedicated to medical device clinical trials and services related to development and commercialization of medical devices.
MediTech joins Medpace as a strategic European acquisition, expanding Medpace’s European device capabilities both in the development of trial designs and regulatory strategies towards CE Mark, in addition to the conduct of clinical trials and authorized representative and quality system support towards ISO 13485. This acquisition, combined with Medpace’s existing medical device division, provides a unique global solution for medical device development, allowing seamless support through all stages of the medical device lifecycle.
MediTech was founded in 2000 by Carla Kikken-Jussen, President & CEO, an industry expert with over 25 years of experience in the medical device industry covering medical device clinical research and European regulatory affairs. MediTech has supported clinical trials on wide variety of medical devices including therapeutic areas such as ophthalmology, cardiovascular, gastroenterology, orthopedics, and pulmonology medical devices. Ms. Kikken-Jussen will continue to lead MediTech with her team members, bringing extensive experience to Medpace.
“I am pleased to welcome Carla Kikken-Jussen and the MediTech team to Medpace,” said Dr. August Troendle, President and CEO, Medpace. “MediTech’s expertise complements and broadens our global medical device service offering. MediTech is well respected in both Europe and the US and this strategic acquisition fully supports Medpace’s growth and provides our sponsors a wide range of regulatory and clinical expertise across North America and Europe along with expanded operational capacity.”
Fairmount Partners represented Medpace in identifying and contacting leading European medical device CROs and represented Medpace in the acquisition of MediTech.
Medpace is a leading global full-service clinical research organization providing Phase I-IV core development services for drug, biologic, and device programs. With medical and regulatory expertise in multiple therapeutic specialties, Medpace has assembled the industry’s most experienced and therapeutically focused teams to execute at every level of the company’s operations, providing complete and seamless drug development services. Medpace creates strategic partnerships with pharmaceutical and biotechnology companies to provide the most efficient and cost-effective path to drug development – from program planning and execution to product approval.
With more than 1200 employees and clinical trial experience in over 40 countries, Medpace has the global reach and capability to conduct studies and navigate regulatory requirements worldwide. In addition to Phase II-IV development services, Medpace provides Phase I / IIA clinical services from Medpace Clinical Pharmacology, central laboratory and therapeutically specialized testing from Medpace Reference Laboratories, complete bioanalytical services in all stages of drug development from Medpace Bioanalytical Laboratories, centralized imaging core laboratory management and reading from Imagepace, and medical device development from Medpace Medical Device.
Visit the Medpace website at www.medpace.com
About MediTech Strategic Consultants B.V.
MediTech Strategic Consultants B.V. (MediTech) is a full service international Contract Research Organization (CRO) focused on Clinical, Regulatory, Clinical Specialist and Quality Consulting and Authorized Representative services with a staff of more than 40 highly qualified team members in the areas of ophthalmology, cardiovascular, gastroenterology, orthopedics, and pulmonology.
MediTech’s team member’s extensive clinical, regulatory and quality experience is complemented by multilingual and cross cultural fluency. The multinational staff are based in The Netherlands HQ office with additional professionals in the Czech Republic, Israel and Poland who offer comprehensive support services to meet our client’s needs for clinical trials conducted throughout the European Union and Israel, Norway, Switzerland and Turkey. The MediTech team can provide all the clinical, regulatory and quality guidance and project support you require.
Visit the MediTech B.V. website at: www.meditech.nl
About Fairmount Partners
Fairmount Partners is one of the largest investment banking groups in the Mid-Atlantic region. The firm specializes in advising middle-market growth companies with mergers and acquisitions, capital raising and strategic advice. Fairmount’s key focus areas include: Healthcare, IT and Business Services, Software & Technology and Industrial & Consumer businesses. Fairmount’s Pharmaceutical Services group is the most active investment bank in the field – with over 90 completed transactions with parties in 14 countries in North and South America, Europe, Asia and Australia, including transactions with nearly all of the leading CROs in the world.
For more information, visit: www.fairmountpartners.com.
Principals of Fairmount Partners acted as advisors to Medpace in this transaction.
Contact: Neal McCarthy